A predictive biomaker and novel drug target for Lung Cancer
Research at the University of Aberdeen analysing the Non Small Cell Lung Cancer (NSCLC) transcriptome revealed a number of biomarkers whose expression profile when monitored in patients predicts response to chemotherapy with platinum based drugs. Resistance to these drugs is a major problem with only 30-40% responding to treatment. The planned development of a diagnostic test for these markers will enable individual patient treatment plans to be drawn up to best tackle NSCLC, a disease with very poor prognosis. One of the biomarkers discovered is Serpin B3. This lysosomal protease inhibitor is a negative regulator of programmed cell death. Exciting data from the Aberdeen team suggests that expression of Serpin B 3 prevents cancer cell death through the lysosomal mediated alternative cell death pathway. This makes it an attractive therapeutic target. The University is keen to develop this technology and is actively seeking parties interested in licensing and co-development.Key Benefits
- For first time offers personalised anti cancer treatment strategy for NSCLC
- Offers chance to improve clinical out comes
- Exciting new drug target for a disease where new and existing therapies are not improving patient prognosis.
-
Applications
- Medical diagnostics
- Biotech / Pharma drug development
IP Status
A patent has been filed for use as a biomarker of response and as a novel target in anti cancer drug development
If you would like further information about
this opportunity please fill out the form below. Your enquiry will
be passed on to the relevant University who will respond to you directly.
